Human ovarian cancer xenografts in nude mice: Chemotherapy trials with paclitaxel, cisplatin, vinorelbine and titanocene dichloride

Anti-Cancer Drugs

Volumn 9, Issue 6, 1998, Pages 557-563

  Villena Heinsen, C ^a,b   Friedrich, M ^a   Ertan, A K ^a   Farnhammer, C ^a   Schmidt, W ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Cisplatin; Nude mice; Paclitaxel; Titanocene dichloride; Tumor growth; Vinorelbine

Indexed keywords

CISPLATIN; NAVELBINE; PACLITAXEL; TITANOCENE DICHLORIDE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER STAGING; COMPARATIVE STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 0031820704     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199807000-00007     Document Type: Article

References (37)

1. Hunter RW, Alexander ND, Soutier WP. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Amer J Obstet Gynec 1992; 166: 504-11.
2. Thigpen JT. Chemotherapy in the management of celomic epithelial carcinoma of the ovary. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press 1993: 277-86.
3. Williams CJ, Stewart L, Pharmar M, Guthrie D. Metaanalysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group. Semin Oncol 1992; 19: 120-8.
4. Edmonson JH, Su J, Krook JE. Treatment of ovarian cancer in elderly women. Mayo Clinic-North Central Cancer Treatment Group studies. Cancer 1983; 71: 261-77
5. Gershenson DM, Mitchell MF, Atkinson N. Age contrast in patients with advanced epithelial ovarian cancer: the MD Anderson Cancer Center experience. Cancer 1993; 71: 638-43.
6. Thigpen JT, Bertelsen K, Eisenhauer EA, Hacker NF, Lund B, Sessa C. Longterm follow-up of patients with advanced ovarian carcinoma treated with chemotherapy. Ann Oncol 1993; 4: 35-40.
7. Pfleiderer A. Tumor reduction and chemotherapy in ovarian cancer. Bailliere's Clin Obstet Gynecol 1989; 3: 119-28.
8. McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Clarke-Pearson DL. A phase III trial of dose-intense (DI) vs. standard-dose (DS) cisplatin (CDDP) and cytoxan (CTX) in advanced ovarian cancer (AOC). Proc Am Soc Clin Oncol 1995; 11: A718.
9. Frasci G, Comella G. Carboplatin-hexamethylmelamineoral etoposide first-line treatment of ovarian cancer patients with bulky disease: a phase II study, Gynec Oncol 1995; 58: 68-73.
10. Roussakis C, Pouchus YF, Gratas C. In vivo study of vinorelbine associations with cisplatin, 5-fluorouracil or actinomycin D relative to a non-small-cell lung carcinoma (NSCLCN6-L16). Anticancer Drug Res 1993; 8: 165-71.
11. Etièvant C, Kruczynski A, Pauwels O. The combination of the tetrazolium derivative reduction (MTT) and digital cell image analysis to monitor in vitro the cytotoxicity of antineoplastic drugs. Anticancer Res 1991; 11: 305-12.
12. Kohayashi S, Sakai T, Dalrymple, PD. Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. Arzneim Forsch 1993; 43: 1367-77.
13. Van Tellingen O, Kuijpers A, Beijnen JH. Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid Chromatography. Invest New Drugs 1993; 11: 141-50.
14. Boré P, Rahmani R, van Cantfort J. Pharmacokinetics of a new anticancer drug, navelbine, in patients. Cancer Chemother Pharmacol 1989; 23: 247-51.
15. Zhou XJ, Rahmani R. Preclinical and clinical pharmacology of vincaalkaloids. Drugs 1992; 44(suppl 4): 1-16.
16. Romero A, Rahinovich MG, Vallejo CT. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 1994; 12: 336-41.
17. Moebius VJ, Stein R, Kieback DG, Runnebaum IB, Sass G, Kreienberg R. Antitumor activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivates. Anticancer Res 1997; 17: 815-22.
18. Köpf-Maier P. Tumor inhibition by titanocene complexes: influence on xenografted human adenocarcinomas of the gastrointestinal tract. Cancer Chemother Pharmacol 1989; 23: 225-30.
19. Kurbacher CM, Nagel W, Mallmann P, et al. In vitro activity of titanocenedichloride in human renal cell carcinoma compared to conventional antineoplastic agents. Anticancer Res 1994; 14: 1529-34.
20. Harstrick A, Schmoll HJ, Sass G, Poliwoda H, Rustum Y. Titanocendichloride activity in cisplatin and doxoruibicin-resistant human ovarian carcinoma cell lines. Eur J Cancer 1993; 27: 1000-2.
21. Köpf-Maier P. Complexes of metals other than platinum as antitumor agents. Eur J Clin Pharmacol 1994; 47: 1-16.
22. Kurbacher CM, Bruckner HW, Andreotti PE, Kurbacher JA, Sass G, Krebs D. In vitro activity of titanocenedichloride versus cisplatin in four ovarian cell lines evaluated by microtiter plate bioluminescence assay. Anti-Cancer Drugs 1995; 6: 697-704.
23. Cao S, Durrani FA, Baumgart J, Sass G, Rustum Y. Titanocene dichloride a new organometallic compound, active in vivo against varieties of human tumors with differential sensitivity to doxorubicin and cisplatin. Proc Am Ass Cancer Res 1995; 36: 391.
24. Köpf-Maier P. Intracellular localization of titanium within xenografted sensitive human tumors after treatment with the antitumor agent titanocene dichloride. J Struct Biol (J Ultrastruct Mol Struct Res) 1990; 105: 35-45.
25. Christodoulou C, Ferry D, Fyfe D, et al. Phase I clinical trial of titanocene dichloride (TD) with pharmacocinetic analysis. Proc Am Ass Cancer Res 1997; 38: 1495.
26. Berdel WE, Schmoll HJ, Scheulen ME, Korfel A, Gründel O, Harstrick A. Phase I clinical and pharmacokinetic study of titanocene dichloride in advanced solid tumors. Proc Am Soc Clin Oncol 1995; 14: 1512.
27. Köpf-Maier P, Köpf H. Metallocene complexes: organometallic antitumor agents. Drugs of the Future 1986; 11: 297-319.
28. Venditti JM. Preclinical drug development: rationale and methods. Semin Oncol 1981; 8: 349-61.
29. Goldstein RS, Mayor GH. Minireview: the nephrotoxicity of cisplatin. Life Sci 1983; 32: 685-90.
30. Cvitkovic E, Izzo J. The current and future place of vinorelbine in cancer therapy. Drugs 1992; 44(suppl 1): 36-45.
31. Weber B, Vogel C, Jones S. A US multicenter phase II trial of Navelbine in advanced breast cancer. Proc Am Soc Clin Oncol 1993; 12: 61 (abstr 46).
32. Coppola F, Balbiani L, Blajman C. Vinorelbine (VNB) containing regimens in three different schedules for the treatment of advanced breast cancer (ABC). Proc Am Soc Clin Oncol 1994; 13: 85 (abstr 144).
33. Ferrera JM, Wendling JL, Hoch M. Mitoxantrone (MTZ)-vinorelbine (VNR) as first line chemotherapy (CT) in metastatic breast cancer (MBC): a pilot study. Proc Am Soc Clin Oncol 1993; 12: 108 (abstr 234).
34. Scheithauer W, Kornek G, Haider K. Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C. Breast Cancer Res Treat 1993; 26: 49-53.
35. Héron JF, George MJ, Kerbrat P. Phase II study of Navelbine as second or third line treatment in advanced ovarian carcinoma. In: Solal Celigny P, ed. Navelbine (vinorelbine). Update and new trends. Montrouge: John Libbey Eurotext 1991: 231-6.
36. Pinel MC, Pinon G, Goudier MJ. Study of the combination vinorelbine-hexamethyl-melamine (V-H) in advanced ovarian adenocarcinoma: preliminary results of a phase I-II study NHO-88, from the ARTAC multicentric ovarian carcinoma study group. In: Solal-Celigny P, ed. Navelbine (vinorelbine). Update and new trends. Montrouge: John Libbey Eurotext 1991: 237-53.
37. Burger RA, DiSaia PJ, Boyle J. Phase II trial of Navelbine in the treatment of women with advanced epithelial ovarian cancer. Gynecol Oncol 1993; 50: 268-9 (abstr 15).